title: Optimizing cardio-oncology programs for cancer patients.
authors.affiliation: Cardio-Oncology Program, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Sanjeev A
authors.initials: SA
authors.lastname: Francis
authors.affiliation: Cardio-Oncology Program, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Aarti
authors.initials: A
authors.lastname: Asnani
authors.affiliation: Cardio-Oncology Program, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Tomas
authors.initials: T
authors.lastname: Neilan
authors.affiliation: Cardio-Oncology Program, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Marielle
authors.initials: M
authors.lastname: Scherrer-Crosbie
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002309:Cardiology / Q000379:methods* / Q000458:organization & administration; D066126:Cardiotoxicity / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D008404:Massachusetts; D008495:Medical Oncology / Q000379:methods* / Q000458:organization & administration; D009369:Neoplasms / Q000628:therapy*
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents
keywords: anthracycline; cardio-oncology; cardiotoxicity; cardiovascular screening; chemotherapy-induced cardiomyopathy; radiation-associated heart disease; survivorship